Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK13 | O15264 | 9/20 | 1.00 |
| ▸ | MAPK12 | P53778 | 9/20 | 1.00 |
| ▸ | MAPK11 | Q15759 | 9/20 | 1.00 |
| ▸ | MAPK14 | Q16539 | 9/20 | 1.00 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.49 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.49 |
| ▸ | RPS6KA3 | P51812 | 1/20 | 0.49 |
| ▸ | RAF1 | P04049 | 2/20 | 0.48 |
| ▸ | MAPK9 | P45984 | 2/20 | 0.48 |
| ▸ | SOAT1 | P35610 | 2/20 | 0.47 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18797648 | 1.00 | MAPK13 (1.00) | MAPK13MAPK12MAPK11MAPK14CSNK1A1 | |
| SCHEMBL20555598 | 1.00 | MAPK13 (1.00) | MAPK13MAPK12MAPK11MAPK14CSNK1A1 | |
| Bromide SCHEMBL5770111 | 0.98 | MAPK13 (0.97) | MAPK13MAPK12MAPK11MAPK14CSNK1A1 | |
| Hydrochloric Acid SCHEMBL5768856 | 0.98 | MAPK13 (0.97) | MAPK13MAPK12MAPK11MAPK14CSNK1A1 | |
| SCHEMBL5772040 | 0.96 | MAPK13 (1.00) | MAPK13MAPK12MAPK11MAPK14CSNK1A1 | |
| SCHEMBL29437788 | 0.96 | MAPK13 (1.00) | MAPK13MAPK12MAPK11MAPK14CSNK1A1 | |
| SCHEMBL5767876 | 0.93 | MAPK13 (0.87) | MAPK13MAPK12MAPK11MAPK14CSNK1A1 | |
| SCHEMBL5770557 | 0.92 | MAPK13 (0.85) | MAPK13MAPK12MAPK11MAPK14CSNK1A1 | |
| SCHEMBL5771142 | 0.91 | MAPK13 (0.84) | MAPK13MAPK12MAPK11MAPK14CSNK1A1 | |
| SCHEMBL5772600 | 0.90 | MAPK11 (0.82) | MAPK13MAPK12MAPK11MAPK14CSNK1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12145981-B2 | Methods and compounds for the treatment or prevention of severe influenza | Poolbeg Pharma (UK) Limited (GB) | 2024-11-19 | — | — | US | claimed |
| US-11339207-B2 | Methods and compounds for the treatment or prevention of severe influenza | ORPH PHARMA IP COMPANY LIMITED (GB) | 2022-05-24 | — | — | US | claimed |
| US-6989395-B2 | Imidazolyl-cyclic acetals | AVENTIS PHARMA LIMITED (GB) | 2006-01-24 | — | — | US | claimed |
| US-20040038991-A1 | Imidazolyl-cyclic acetals | AVENTIS PHARMA LIMITED (GB) | 2004-02-26 | — | — | US | claimed |
| EP-0988301-A1 | IMIDAZOLYL-CYCLIC ACETALS | RHONE-POULENC RORER LIMITED (GB) | 2000-03-29 | — | — | EP | claimed |
| WO-1998056788-A1 | IMIDAZOLYL-CYCLIC ACETALS | RHONE-POULENC RORER LIMITED (GB) | 1998-12-17 | — | — | WO | claimed |
| US-20260115177-A1 | MEDICINAL PRODUCTS AND METHODS FOR THE ALLEVIATION OF CANCER IMMUNOTHERA-PY-ASSOCIATED CYTOKINE RELEASE SYNDROME | POOLBEG PHARMA UK LTD (GB) | 2026-04-30 | — | — | US | disclosed |
| EP-4648772-A1 | MEDICINAL PRODUCTS AND METHODS FOR THE ALLEVIATION OF CANCER IMMUNOTHERAPY-ASSOCIATED CYTOKINE RELEASE SYNDROME | Poolbeg Pharma (UK) Limited (GB) | 2025-11-19 | — | — | EP | disclosed |
| US-20250002844-A1 | GENERATION AND MAINTENANCE OF STEM CELLS | THE SCRIPPS RESEARCH INSTITUTE | 2025-01-02 | — | — | US | disclosed |
| US-12054741-B2 | Generation and maintenance of stem cells | THE SCRIPPS RESEARCH INSTITUTE (US) | 2024-08-06 | — | — | US | disclosed |
| WO-2024150014-A1 | MEDICINAL PRODUCTS AND METHODS FOR THE ALLEVIATION OF CANCER IMMUNOTHERAPY-ASSOCIATED CYTOKINE RELEASE SYNDROME | Poolbeg Pharma (UK) Limited (GB) | 2024-07-18 | — | — | WO | disclosed |
| US-11332716-B2 | Methods and compositions for producing pancreatic beta cells | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2022-05-17 | — | — | US | disclosed |
| EP-3081568-B1 | COMPOSITIONS AND METHODS FOR TREATING ALZHEIMER'S DISEASE | EIP PHARMA LLC (US) | 2019-11-13 | — | — | EP | disclosed |
| US-20120289511-A1 | COMPOSITIONS AND METHODS FOR TREATING ALZHEIMER'S DISEASE | EIP PHARMA, LLC (US) | 2012-11-15 | — | — | US | disclosed |
| EP-0988301-B1 | IMIDAZOLYL-CYCLIC ACETALS | AVENTIS PHARMA LTD (GB) | 2006-08-09 | — | — | EP | disclosed |
| US-6989395-B2 | Imidazolyl-cyclic acetals | AVENTIS PHARMA LIMITED (GB) | 2006-01-24 | — | — | US | disclosed |
| US-20040038991-A1 | Imidazolyl-cyclic acetals | AVENTIS PHARMA LIMITED (GB) | 2004-02-26 | — | — | US | disclosed |
| US-6602877-B1 | Imidazolyl-cyclic acetals | AVENTIS PHARMA LIMITED (GB) | 2003-08-05 | — | — | US | disclosed |
| EP-0988301-A1 | IMIDAZOLYL-CYCLIC ACETALS | RHONE-POULENC RORER LIMITED (GB) | 2000-03-29 | — | — | EP | disclosed |
| WO-1998056788-A1 | IMIDAZOLYL-CYCLIC ACETALS | RHONE-POULENC RORER LIMITED (GB) | 1998-12-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12145981-B2 | Methods and compounds for the treatment or prevention of severe influenza | CXCL10, MAPK10, CCL11 | MAPK13 23/4885MAPK12 12/4885MAPK11 26/4885 |
| US-11332716-B2 | Methods and compositions for producing pancreatic beta cells | IAPP, ALPG, AMY2A | MAPK13 4379/4885MAPK12 4485/4885MAPK11 4239/4885 |
| US-20040038991-A1 | Imidazolyl-cyclic acetals | CBR1, LBR, CBR3 | MAPK13 1610/4885MAPK12 2766/4885MAPK11 1125/4885 |
| US-20120289511-A1 | COMPOSITIONS AND METHODS FOR TREATING ALZHEIMER'S DISEASE | APP, PSEN1, PSEN2 | MAPK13 4673/4885MAPK12 4165/4885MAPK11 4249/4885 |
| US-20260115177-A1 | MEDICINAL PRODUCTS AND METHODS FOR THE ALLEVIATION OF CANCER IMMUNOTHERA-PY-ASSOCIATED CYTOKINE RELEASE SYNDROME | MAPK13, MAPK11, MAPK1 | MAPK13 1/4885MAPK12 5/4885MAPK11 2/4885 |
| US-11339207-B2 | Methods and compounds for the treatment or prevention of severe influenza | CXCL10, MAPK10, MAPK1 | MAPK13 20/4885MAPK12 11/4885MAPK11 24/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.